{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T16:45:18Z","timestamp":1747154718188,"version":"3.40.5"},"reference-count":19,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ajpm-online.net","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Medicine"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.amepre.2015.04.031","type":"journal-article","created":{"date-parts":[[2015,7,17]],"date-time":"2015-07-17T03:20:10Z","timestamp":1437103210000},"page":"761-764","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Examining Fluoroquinolone Claims Among Gonorrhea-Associated Prescription Drug Claims, 2000\u20132010"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4519-2857","authenticated-orcid":false,"suffix":"Jr.","given":"Kwame","family":"Owusu-Edusei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danya S.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas L.","family":"Gift","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2014","series-title":"Sexually Transmitted Disease Surveillance, 2013","key":"10.1016\/j.amepre.2015.04.031_bib1"},{"issue":"3","key":"10.1016\/j.amepre.2015.04.031_bib2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/OLQ.0b013e318286bb53","article-title":"Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008","volume":"40","author":"Satterwhite","year":"2013","journal-title":"Sex Transm Dis"},{"issue":"3","key":"10.1016\/j.amepre.2015.04.031_bib3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/OLQ.0b013e318285c6d2","article-title":"The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008","volume":"40","author":"Owusu-Edusei","year":"2013","journal-title":"Sex Transm Dis"},{"issue":"14","key":"10.1016\/j.amepre.2015.04.031_bib4","first-page":"332","article-title":"Update to CDC\u2019s sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections","volume":"56","year":"2007","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"37","key":"10.1016\/j.amepre.2015.04.031_bib5","first-page":"833","article-title":"Fluoroquinolone-resistance in Neisseria gonorrhoeae, Hawaii, 1999, and decreased susceptibility to azithromycin in N. gonorrhoeae, Missouri, 1999","volume":"49","author":"CDC","year":"2000","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"46","key":"10.1016\/j.amepre.2015.04.031_bib6","first-page":"1041","article-title":"Increases in fluoroquinolone-resistant Neisseria gonorrhoeae\u2014Hawaii and California, 2001","volume":"51","year":"2002","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"16","key":"10.1016\/j.amepre.2015.04.031_bib7","first-page":"335","article-title":"Increases in fluoroquinolone-resistant Neisseria gonorrhoeae among men who have sex with men\u2014United States, 2003, and revised recommendations for gonorrhea treatment, 2004","volume":"53","year":"2004","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.amepre.2015.04.031_bib8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2105\/AJPH.2011.300283","article-title":"Changes in fluoroquinolone use for gonorrhea following publication of revised treatment guidelines","volume":"102","author":"Dowell","year":"2012","journal-title":"Am J Public Health"},{"issue":"4","key":"10.1016\/j.amepre.2015.04.031_bib9","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1071\/SH14057","article-title":"Declining trends in the proportion of non-viral sexually transmissible infections reported by STD clinics in the US, 2000-10","volume":"11","author":"Owusu-Edusei","year":"2014","journal-title":"Sex Health"},{"key":"10.1016\/j.amepre.2015.04.031_bib10","unstructured":"Truven Health Analytics. Marketscan Research Database: User Guide and Database Dictionary. Ann Arbor, MI,: Truven Health Analytics; 2012."},{"key":"10.1016\/j.amepre.2015.04.031_bib11","unstructured":"Truven Health Analytics. Marketscan Research Database: User Guide and Database Dictionary. Ann Arbor, MI,: Truven Health Analytics; 2011."},{"key":"10.1016\/j.amepre.2015.04.031_bib12","unstructured":"Truven Health Analytics. MarketScan Research. 2015. www.marketscan.truvenhealth.com\/marketscanportal\/portal.aspx."},{"issue":"8","key":"10.1016\/j.amepre.2015.04.031_bib13","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/OLQ.0b013e3181d73e4c","article-title":"The direct cost of chlamydial infections: estimates for the employer-sponsored privately insured population in the United States, 2003-2007","volume":"37","author":"Owusu-Edusei","year":"2010","journal-title":"Sex Transm Dis"},{"issue":"5","key":"10.1016\/j.amepre.2015.04.031_bib14","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/OLQ.0b013e3181c5e643","article-title":"Treatment cost of acute gonococcal infections: estimates from employer-sponsored private insurance claims data in the United States, 2003-2007","volume":"37","author":"Owusu-Edusei","year":"2010","journal-title":"Sex Transm Dis"},{"issue":"3","key":"10.1016\/j.amepre.2015.04.031_bib15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/OLQ.0b013e3181f4207f","article-title":"Estimating the direct outpatient medical cost per episode of primary and secondary syphilis in the United States: insured population perspective, 2003-2007","volume":"38","author":"Owusu-Edusei","year":"2011","journal-title":"Sex Transm Dis"},{"issue":"RR-12","key":"10.1016\/j.amepre.2015.04.031_bib16","first-page":"1","article-title":"Sexually transmitted diseases treatment guidelines, 2010","volume":"59","author":"Workowski","year":"2010","journal-title":"MMWR Recomm Rep"},{"issue":"RR-11","key":"10.1016\/j.amepre.2015.04.031_bib17","first-page":"1","article-title":"Sexually transmitted diseases treatment guidelines, 2006","volume":"55","author":"Workowski","year":"2006","journal-title":"MMWR Recomm Rep"},{"issue":"suppl 4","key":"10.1016\/j.amepre.2015.04.031_bib18","doi-asserted-by":"crossref","first-page":"iv5","DOI":"10.1136\/sextrans-2013-051162","article-title":"Trends in antimicrobial resistance in Neisseria gonorrhoeae in the USA: the Gonococcal Isolate Surveillance Project (GISP), January 2006-June 2012","volume":"89","author":"Kirkcaldy","year":"2013","journal-title":"Sex Transm Infect"},{"issue":"8","key":"10.1016\/j.amepre.2015.04.031_bib19","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/00007435-199909000-00001","article-title":"Completeness of and duration of time before treatment after screening women for Chlamydia trachomatis infections","volume":"26","author":"Foglia","year":"1999","journal-title":"Sex Transm Dis"}],"container-title":["American Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379715002159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379715002159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T07:42:01Z","timestamp":1652859721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749379715002159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0749379715002159"],"URL":"https:\/\/doi.org\/10.1016\/j.amepre.2015.04.031","relation":{},"ISSN":["0749-3797"],"issn-type":[{"type":"print","value":"0749-3797"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Examining Fluoroquinolone Claims Among Gonorrhea-Associated Prescription Drug Claims, 2000\u20132010","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amepre.2015.04.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}